Accession Number : ADA323874
Title : A New Immunologic Method for Detection of Occult Breast Cancer.
Descriptive Note : Annual rept. 1 Oct 95-30 Sep 96,
Corporate Author : JOHN WAYNE INST FOR CANCER TREATMENT AND RESEARCH SANTA MONICA CA
Personal Author(s) : Gupta, Rishab K.
PDF Url : ADA323874
Report Date : OCT 1996
Pagination or Media Count : 20
Abstract : Analyses of pre- and post-operative serum samples from 128 breast cancer patients for the 90kDa glycoprotein TAA-specific immune complexes (TAA-IC) and correlation of the results with clinical follow-up of these patients for five years revealed that the TAA-IC is useful in identifying breast cancer patients who harbor occult micrometastases, or are at high risk of developing recurrent disease after surgical resection of the disease. This assay, like most other tumor markers is not 100% accurate. There are some false positives and some false negatives; however, these false predictive values are less significant than many other markers commonly used. We have studied the immunobiology of the 90kDa glycoprotein TAA to the extent that the false positive and negative results are reasonably explained. In addition, a new breast tumor-associated antigen (B-TAA) which is recognized by allogenic serum samples from breast cancer patients has been identified in NP-40 extract of breast cancer cell lines. A lymphoblastoid cell line (LCL-4) from immortalization of a breast cancer patient's B-cells by EBV transformation has been established. This lymphoblastoid cell line continues to secrete IgM antibodies that react with breast cancer cell extracts and spent medium.
Descriptors : *CLINICAL MEDICINE, *BLOOD SERUM, *CELLS(BIOLOGY), *BREAST CANCER, DETECTION, HIGH RATE, RISK, NEOPLASMS, CORRELATION, SAMPLING, ANTIBODIES, MARKERS, PATIENTS, IMMUNOLOGY, LYMPHOCYTES, SCREENS(DISPLAYS), PHOTOGRAPHIC NEGATIVES, ALLERGIC DISEASES.
Subject Categories : Anatomy and Physiology
Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE